J&J Reaches Proposed Settlement in Ovarian Talc Litigation
JNJ sits 70% above its 52-week low of $164.23.
Summary
Johnson & Johnson has reached a proposed settlement to resolve its ovarian talc litigation, committing $5.5 billion to resolve roughly 76,000 remaining claims. The agreement is conditioned on the express participation of at least 95% of those claims. The settlement calls for a first payment of no more than $3 billion to be made in 2027, with no additional payments due before 2028. The company maintains that the talc claims are based on junk science, a position it says recent court developments have affirmed. This resolution would eliminate the expense associated with litigating the remaining ovarian talc claims, removing a key uncertainty that has weighed on the stock. The development follows years of litigation and the Supreme Court's refusal to hear appeals in May, and comes amid J&J's strong operational performance including a Q2 beat and raised guidance.
Updates
· Dow Jones Newswires — Plaintiffs acknowledged they cannot prove specific causation, a key legal concession reducing future liability risk. Shares rose 1.9% after hours to $270.88.
At the time of this announcement, JNJ was trading at $280.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $640.9B. The 52-week trading range was $164.23 to $269.43. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Dow Jones Newswires.